INZOBOON 1000 TABLET

💠 Imeglimin 1000mg Tablet

A Novel Agent for Type 2 Diabetes Management

---

🔍 What Is Imeglimin?

Imeglimin is a first-in-class oral antidiabetic medication approved for the treatment of Type 2 Diabetes Mellitus (T2DM). It represents a new chemical class called “glimins” and offers a multifactorial approach to glycemic control by:

• Enhancing insulin sensitivity

• Improving beta-cell function

• Reducing hepatic gluconeogenesis

• Supporting mitochondrial function

---

🧪 Ingredient

• Imeglimin Hydrochloride – 1000mg per tablet.

---

💊 How to Use

• Dosage: The usual dose is 1000 mg twice daily (morning and evening), with meals to reduce the risk of gastrointestinal side effects.

• Administration: Swallow whole with water; do not crush or chew.

• Adjustments: No dose adjustment required in mild to moderate renal impairment, but not recommended in severe renal or hepatic dysfunction unless otherwise advised.

---

⚠️ Common Side Effects

Imeglimin is generally well tolerated. Common side effects include:

• Nausea

• Diarrhea

• Abdominal discomfort

• Headache

• Fatigue

These are usually mild and transient, especially when taken with meals.

---

🚨 Serious Side Effects (Rare, Seek Medical Help)

Though rare, serious side effects may occur:

• Lactic acidosis (very rare but theoretically possible due to its mitochondrial action)

  • Symptoms: Rapid breathing, confusion, abdominal pain, muscle pain

• Allergic reactions

  • Rash, swelling, itching, breathing difficulty

• Severe gastrointestinal upset: Persistent vomiting or diarrhea leading to dehydration

---

🔍 Monitoring & Follow-Up

Patients on Imeglimin should be monitored regularly:

• Blood glucose: Fasting and postprandial

• HbA1c: Every 3 months to assess long-term control

• Renal function (eGFR): Periodically, especially in elderly or those with known impairment

• Liver function tests: If symptoms of hepatic dysfunction occur

---

⚠️ Warnings & Precautions

• Not for Type 1 Diabetes or diabetic ketoacidosis

• Caution in renal impairment: Safe in mild-to-moderate cases (eGFR ≥45 ml/min/1.73m²); avoid if severely impaired

• Pregnancy & Breastfeeding: Not enough data; avoid unless benefits outweigh risks

• Hypoglycemia risk: Low when used alone, but increased when combined with sulfonylureas or insulin

• Drug interactions: Minimal known interactions, but avoid combining with nephrotoxic agents unless monitored

---

✅ Summary

Imeglimin 1000mg is a novel, first-in-class oral antidiabetic drug offering a unique triple mechanism that targets insulin resistance, improves pancreatic beta-cell function, and reduces excessive hepatic glucose output. It is well tolerated and ideal as monotherapy or add-on therapy in Type 2 diabetes patients. With minimal risk of hypoglycemia and good tolerability, it is a promising option in modern diabetes care. Proper monitoring of renal function and glycemic control is essential for safe and effective use. It is not intended for Type 1 diabetes or as a substitute for insulin in severe cases.

Note: This information is intended for educational purposes and should not replace professional medical advice. Always consult a healthcare provider for personalized guidance.